Nova Mentis Life Science Corp (OTCMKTS: NMLSF) Concludes Research on Oral Microdose Psilocybin

Nova Mentis Life Science Corp. (OTCMKTS: NMLSF) recently announced that it concluded its investigation on the psilocybin preclinical study. The company conducted the study at the Rome Tre University in Italy, which concluded that a small dose of its psilocybin drug developed behavioral and cognitive defects.  

The findings will help the company move to Phase 2A trials

The altered behavioral defects included recognition memory while testing a genetic model of the X syndrome. As a result, NMLSF and the university’s collaboration develop fulfilling clinical trials results that surpass investors’ expectations. One of the leading scientists, Dr. Viviana Trezza, stated that the findings are crucial in preparing clinical trials for Phase 2A research.

Dr. Trezza further added that the team would submit the results of the microdose therapy to Health Canada, which accompanies an application stating the intention of the study. NMLSF confirms that its research on the compound also works as a treatment for Autism patients, thus enabling memory recognition.

Autism disorder is a severe neurodevelopment disorder with no recorded form of treatment. Autism Disorder develops from a fragile X syndrome, a common type of intellectual genetic disability that increases an individual’s acquiring the disorder. Dr. Terrez reiterated that the research goal was to investigate the doses of NMLSF’s psilocybin.

How the company tested the drug

NMLSF conducted the psilocybin experiments on genetically modified rats that assisted it in answering phenomena such as if its psilocybin could be a potential treatment for Autism. In addition, the company tested its compound on a developed form of FXS (1) for two weeks. Finally, NMLSF compared these results with genetic rats that received macro dose therapy: however, the company’s compound highlighted no side effects or hallucinogenic factors.

The company’s headquarters is in Canada is among the world’s leading companies in cultivating and producing therapeutics diagnoses for certain neuroinflammatory disorders. In addition, NOVA created the psilocybin orphan drug in areas such as the European Union, among others.

The company aims to develop and diagnose certain persistent illnesses or disorders that do not have treatments. These illnesses investigated by NMLSF include Fragile X syndrome, among others, thus creating drugs that yield low to no side effects.